CoChat

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index; 210 of the 306 sources its claims cite were checked for support.

Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients

Open access

Abstract

Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor. The amount of bone removed in an OS patient leaves too large of a deficit for bone to form on its own and requires reconstruction with metal implants or allografts. Both methods require the bone to heal, either to the implant or across the allograft junction, often in the setting of marrow-killing chemotherapy. Therefore, the issue of bone regeneration within the surgically resected margins remains an important challenge for the patient, family, and treating providers. Mesenchymal stem/stromal cells (MSCs) are potential agents for enhancing bone regeneration post tumor resection. MSCs, used with scaffolds and growth factors, show promise in fostering bone regeneration in OS cases. We spotlight two MSC types—bone marrow-derived (BM-MSCs) and adipose tissue-derived (ASCs)—highlighting their bone regrowth facilitation and immunomodulatory effects on immune cells like macrophages and T cells, enhancing therapeutic outcomes. The objective of this review is two-fold: review work demonstrating any ability of MSCs to target the deranged immune system in the OS microenvironment, and synthesize the available literature on the use of MSCs as a therapeutic option for stimulating bone regrowth in OS patients post bone resection. When it comes to repairing bone defects, both MB-MSCs and ASCs hold great potential for stimulating bone regeneration. Research has showcased their effectiveness in reconstructing bone defects while maintaining a non-tumorigenic role following wide resection of bone tumors, underscoring their capability to enhance bone healing and regeneration following tumor excisions.

Overview

CoChat Summary

TL;DR

This narrative review argues that mesenchymal stem/stromal cells (MSCs), especially bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived stem cells (ASCs), may promote bone regeneration after osteosarcoma (OS) tumor excision while also modulating macrophages and T cells. However, MSC effects are context-dependent, can be pro-tumorigenic, and require further safety and delivery optimization before therapeutic use.

Key findings

  • MSCs can exert both pro- and anti-tumorigenic effects; without modulation, the net effect appears pro-tumorigenic, but priming, drug loading, or MSC-derived extracellular vesicles (EVs) may support anti-tumor therapy. For example, IFN-γ priming transiently upregulates MHC-I and MHC-II, and MSC EVs carrying miRNAs such as miR-16-5p, miR-3940-5p, miR-4461, and miR-15a can reduce metastatic potential or suppress tumor growth, angiogenesis, and invasion.
  • BM-MSCs and ASCs show promise for bone regeneration after OS resection. In clinical reports, scaffold-free ASCs in three OS patients produced adequate bone regrowth at 54, 27, and 48 months with no prolonged inflammation or neoplastic growth; two patients receiving 3D osteogenic ASC implants showed osteogenesis without oncological side effects short-term (within 3 months) and long-term (up to 4 years). In another study, all eight patients treated with BM-MSCs in fibrin clots regained limb function at average follow-ups of 6.7 and 76 months, with no excessive tissue growth or tumor development.
  • Safety data are mixed. MSC transplantation/infusion in humans is described as safe in some studies: 226 patients receiving human platelet lysate-expanded MSCs showed no malignant transformation over a mean follow-up of 11 months, and chromosomal abnormalities in culture-expanded MSCs were linked to senescence rather than tumorigenesis. However, animal studies showed MSC infusion can promote OS growth and pulmonary metastasis via CCL5, CXCR4/VEGF, and IL-6/STAT3 signaling; anti-IL-6 receptor antibodies halted the pro-tumor effects of tumor extracellular vesicle-educated MSCs.
  • MSC immunomodulation is bidirectional: MSCs can polarize M1 macrophages toward an M2 anti-inflammatory phenotype, impair T cell responses, and increase Tregs, but can also promote macrophage/T cell activation and CD8+ cytotoxic T cell function while suppressing Tregs. CD146+ and CD106+ MSC subpopulations are highlighted as having higher immunomodulatory potency.

Methods

  • Narrative review with a two-fold objective: review work on MSC ability to target the deranged immune system in the OS microenvironment, and synthesize literature on MSCs for stimulating bone regrowth in OS patients after bone resection.
  • Evidence discussed includes in vitro studies, in vivo animal models such as nude mice and OS xenograft models, and clinical studies/case reports involving BM-MSCs or ASCs with scaffolds, growth factors, drug loading, or EVs.
  • Main analysis is qualitative synthesis of mechanisms, MSC types, bone regeneration strategies, immunomodulatory effects, and safety considerations; no systematic search strategy, quality appraisal, or meta-analysis is described.

Limitations

  • The paper states that further research is needed to fully understand mechanisms of action, optimize MSC delivery methods, and evaluate long-term safety and efficacy. It also lists safety/efficacy challenges in MSC manufacturing, including replacing animal-derived media with regulatory-compliant media, ensuring lack of malignant transformation via genetic stability testing, choosing local versus systemic delivery, and optimizing MSC dose (up to 5 × 10^6 cells/kg of body mass or more).
  • The paper notes that MSC function is context-dependent, influenced by tissue origin and the administered tissue microenvironment; the literature is mixed on whether BM-MSCs or ASCs have superior osteogenic potential, and unknown TME effects could subvert MSCs toward pro-tumorigenic activity. It also states that only a limited number of cell-based strategies have been adopted in clinical practice, and none are definitive for delayed/non-union or bone regrowth after tumor excision.
  • Evident from the text: as a narrative review, it lacks a systematic search, formal risk-of-bias assessment, or meta-analysis, and many conclusions rely on preclinical models and small clinical series.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/bioengineering10101187

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Illustration depicting the dynamic process of bone reconstruction using MSCs, MSCs-derived EVs, and biomaterials following neoadjuvant chemotherapy and surgical resection of OS.
Figure 1 Illustration depicting the dynamic process of bone reconstruction using MSCs, MSCs-derived EVs, and biomaterials following neoadjuvant chemotherapy and surgical resection of OS.CC BY · PubMed Central

Verification

Claims the paper makes

136 Valid · 4 Not valid · 26 Not checked · 20 Own results and interpretations

96 more claims · 73 with their cited sources checked

Create a free account to see all 186 claims and to verify the 39 references still open.

See all claims — free account
  • Probably not a substantial claim. 32
  • It may state two separate claims as one. 60
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 127 references

Cited by

Metadata

Authors
Baron, M., Drohat, P., Crawford, B., Hornicek, F. J., Best, T. M., & Kouroupis, D.
Affiliations
University of Miami (US)
Corresponding author
Kouroupis, Dimitrios
Venue
Bioengineering
Publisher
MDPI AG
Published
2023-10-13
Volume
10
Issue
10
Pages
1187
ISSN
2306-5354 (ISSN-L)
OpenAlex
W4387615496
Cited by
19
References
127
Citations by year
2026: 9 · 2025: 3 · 2024: 7
FWCI
0.89
Type
journal article
Language
en
Open access
Locations
  • Bioengineering (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (5R21AR080388-02)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Keywords
osteosarcoma, mesenchymal stem cells, bone regeneration, immunomodulation, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, tumor resection, bone defect repair, tumor microenvironment, macrophages, T cells, neoadjuvant chemotherapy, bone marrow

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.